149 Startups
  • Sector
  • Participated in
  • Year of participation

Hello R&D

  • 2024
  • Enabling Technology
  • Venture Challenge
Liver toxicity is the main safety reason for drug attrition in clinical trials, causing 1 in every 13 drugs to fail. We have developed a novel, human liver model in a dish called hello which accurately predicts the toxicity of drugs.

Hubrecht Organoid Technology (The HUB)

  • 2010
  • Enabling Technology
  • Other
the HUB provides access to a unique and robust platform that links patient-specific genetic and phenotypic information to preclinical and clinical drug-responsiveness.

Hy2Care

  • 2011
  • Other
  • Therapeutics
Hy2Care develops a so called “injectable plaster” to repair the cartilage surface.

Hybridize

  • 2018
  • Venture Challenge
At Hybridize, we have developed a cost-effective proprietary therapeutic compound that can be intravenously administered to protect the kidney from BKV-mediated damage while maintaining full immunosuppression.

IMcoMet

  • 2019
  • Therapeutics
  • Venture Challenge
Basal cell carcinoma is the most diagnosed cancer worldwide. IMcoMET is developing a novel treatment method that will lead to removal of lesions with only minor side effects.

INBORN

  • 2022
  • Therapeutics
  • Venture Challenge
Injectable bone filler with drug release function for treatment of bone infections (INBORN)

Incircular biotechnologies

  • 2019
  • Enabling Technology
  • Venture Challenge
Incircular Biotechnologies uses its unique patented INCYPRO technology to stabilize G protein-coupled receptors (GPCRs) for reliable applications in drug discovery. This will enable the development of drug candidates for currently non-targeted GPCRs.

Innofluidics

  • 2021
  • Diagnostics
  • Venture Challenge
Liquid biopsy platform for purification and collection of intact CTCs directly from blood

Innofuse

  • 2014
  • Medical Device
  • Venture Challenge
An infusion set that guarantees stability and immediacy of drug administration for preterm babies

inSteps

  • 2022
  • Enabling Technology
  • Venture Challenge
Our in-silico platform can simulate stent-retriever-based thrombectomy in various patient-specific scenarios of varying vascular anatomy and clot characteristics. This allows the medical device industries to evaluate the performance of their novel devices before pre-clinical testing.